Sanofi (SNW DU) stock market data APIs
€77.2101
-0.04(-0.1%)
as of March 17, 2026
Try our APIs with
free plan!
Sanofi Financial Data Overview
Price chart is built with
Anychart
There is no Profile data available for SNW.DU.
Prev. Close
77.2101
Open
77.1701
High
77.4761
Low
77.1116
52 wk Range
75.45-101.6286
Market Cap
108 619 M
EPS
1.78
Dividends (Yield)
0.0363
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Sanofi data using free add-ons & libraries
Get Sanofi Fundamental Data
Sanofi Fundamental data includes:
- Net Revenue:
- EBITDA:
- Earnings Per Share: 0
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2024-04-25
- EPS/Forecast: 1.74
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Sanofi News
New
Mirecule Expands Strategic FSHD Collaboration with Sanofi
GAITHERSBURG, Md., March 18, 2026--(BUSINESS WIRE)--Mirecule, Inc., a leader in Antibody RNA Conjugate (ARC) therapeutics targeting rare neuromuscular diseases, today announced an expansion of its str...
Sanofi R&D Updates Highlight Venglustat Win And In Vivo CAR-T Potential
Never miss an important update on your stock portfolio and cut through the noise. Over 7 million investors trust Simply Wall St to stay informed where it matters for FREE. Sanofi received FDA Breakth...
Sensorion Reports Full-Year 2025 Results, Provides Corporate Update and Announces Release of Annual Report
GJB2-GT (SENS-601) CTA/IND-enabling studies progress, supported by regulatory interactions with FDA and EMA since Q3 2025, and on track for CTA submission in H1 2026 SENS-501 Audiogene trial ongoing;...
Press Release: Sanofi’s venglustat earns Breakthrough Therapy designation in the US for type 3 Gaucher disease
Sanofi Winthrop Industrie Sanofi’s venglustat earns Breakthrough Therapy designation in the US for type 3 Gaucher disease Paris, March 18, 2026. The US Food and Drug Administration (FDA) has gra...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
